Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer : A population-based study in Sweden
(2018) In International Journal of Cancer 142(10). p.2003-2010- Abstract
The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR)... (More)
The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR) of CRC mortality and all-cause mortality associated with post-diagnostic use of hormone therapy. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR = 0.67, 95%CI 0.56–0.79) and a 30% risk reduction in all-cause mortality (HR = 0.68, 95%CI 0.59–0.77). The risk reduction was even stronger if women also used hormone therapy before the diagnosis of CRC and for women with higher cumulative doses of hormone therapy. The risk reduction was largely consistent irrespective of CRC severity. Our data suggests that use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality.
(Less)
- author
- Ji, Jianguang LU ; Sundquist, Jan LU and Sundquist, Kristina LU
- organization
- publishing date
- 2018-05-15
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- all-cause mortality, cause-specific mortality, colorectal cancer, hormone therapy
- in
- International Journal of Cancer
- volume
- 142
- issue
- 10
- pages
- 8 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:29270993
- scopus:85044372731
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.31228
- language
- English
- LU publication?
- yes
- id
- 7d04cd3e-96be-4fe0-9d40-bb5e407b1a05
- date added to LUP
- 2018-04-04 11:04:35
- date last changed
- 2024-08-19 15:57:29
@article{7d04cd3e-96be-4fe0-9d40-bb5e407b1a05, abstract = {{<p>The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR) of CRC mortality and all-cause mortality associated with post-diagnostic use of hormone therapy. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR = 0.67, 95%CI 0.56–0.79) and a 30% risk reduction in all-cause mortality (HR = 0.68, 95%CI 0.59–0.77). The risk reduction was even stronger if women also used hormone therapy before the diagnosis of CRC and for women with higher cumulative doses of hormone therapy. The risk reduction was largely consistent irrespective of CRC severity. Our data suggests that use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality.</p>}}, author = {{Ji, Jianguang and Sundquist, Jan and Sundquist, Kristina}}, issn = {{0020-7136}}, keywords = {{all-cause mortality; cause-specific mortality; colorectal cancer; hormone therapy}}, language = {{eng}}, month = {{05}}, number = {{10}}, pages = {{2003--2010}}, publisher = {{John Wiley & Sons Inc.}}, series = {{International Journal of Cancer}}, title = {{Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer : A population-based study in Sweden}}, url = {{http://dx.doi.org/10.1002/ijc.31228}}, doi = {{10.1002/ijc.31228}}, volume = {{142}}, year = {{2018}}, }